TLX PE Ratio & Valuation, Is TLX Overvalued

Historical Valuation

Telix Pharmaceuticals Ltd (TLX) is now in the Overvalued zone, suggesting that its current forward PE ratio of 207.95 is considered Overvalued compared with the five-year average of 110.33. The fair price of Telix Pharmaceuticals Ltd (TLX) is between 3.19 to 8.26 according to relative valuation method. Compared to the current price of 8.75 USD , Telix Pharmaceuticals Ltd By Overvalued By 5.92%.

Relative Value

Fair Zone

3.19-8.26

Current Price：8.75

5.92%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Telix Pharmaceuticals Ltd (TLX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Telix Pharmaceuticals Ltd (TLX) has a current Price-to-Book (P/B) ratio of 6.04. Compared to its 3-year average P/B ratio of 12.12, the current P/B ratio is approximately -50.18% higher. Relative to its 5-year average P/B ratio of 12.12, the current P/B ratio is about -50.18% higher. Telix Pharmaceuticals Ltd (TLX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 0.23%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 0.23%, the current FCF yield is about -100.00% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TLX competitors is 107.45, providing a benchmark for relative valuation. Telix Pharmaceuticals Ltd Corp (TLX.O) exhibits a P/S ratio of --, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TLX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TLX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TLX currently overvalued or undervalued?

Telix Pharmaceuticals Ltd (TLX) is now in the Overvalued zone, suggesting that its current forward PE ratio of 207.95 is considered Overvalued compared with the five-year average of 110.33. The fair price of Telix Pharmaceuticals Ltd (TLX) is between 3.19 to 8.26 according to relative valuation method. Compared to the current price of 8.75 USD, Telix Pharmaceuticals Ltd is Overvalued By 5.92%.

What is Telix Pharmaceuticals Ltd (TLX) fair value?

TLX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Telix Pharmaceuticals Ltd (TLX) is between 3.19 to 8.26 according to relative valuation method.

How does TLX's valuation metrics compare to the industry average?

The average P/S ratio for TLX's competitors is 107.45, providing a benchmark for relative valuation. Telix Pharmaceuticals Ltd Corp (TLX) exhibits a P/S ratio of --, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Telix Pharmaceuticals Ltd (TLX) as of Mar 25 2026?

As of Mar 25 2026, Telix Pharmaceuticals Ltd (TLX) has a P/B ratio of 6.04. This indicates that the market values TLX at 6.04 times its book value.

What is the current FCF Yield for Telix Pharmaceuticals Ltd (TLX) as of Mar 25 2026?

As of Mar 25 2026, Telix Pharmaceuticals Ltd (TLX) has a FCF Yield of 0.00%. This means that for every dollar of Telix Pharmaceuticals Ltd's market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Telix Pharmaceuticals Ltd (TLX) as of Mar 25 2026?

As of Mar 25 2026, Telix Pharmaceuticals Ltd (TLX) has a Forward P/E ratio of 207.95. This means the market is willing to pay $207.95 for every dollar of Telix Pharmaceuticals Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Telix Pharmaceuticals Ltd (TLX) as of Mar 25 2026?

As of Mar 25 2026, Telix Pharmaceuticals Ltd (TLX) has a Forward P/S ratio of 0.00. This means the market is valuing TLX at $0.00 for every dollar of expected revenue over the next 12 months.

TLX Valuation